SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OTC:BB- JRSE

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: vcap who wrote ()3/1/1999 9:48:00 AM
From: T A P  Read Replies (1) of 72
 
Monday March 1, 8:01 am Eastern Time

Company Press Release

Jacobson Resonance Signs First
License Agreement for Distribution
Throughout Europe, Middle East and
Africa

BOCA RATON, Fla.--(BUSINESS WIRE)--March 1, 1999--Jacobson Resonance Enterprises
Inc. (OTC BB:JRSE - news) announced that the company has granted a 10-year License
Agreement to Serrato Enterprises L.L.C. to market and distribute its products in Europe, Africa and
the Middle East (excluding Israel and the nations that made up the former USSR).

Serrato Enterprises, as part of this agreement, is applying on Jacobson Resonance's behalf for the
Certificate of Conformance (CE-Mark) in the European Common Market based on Jacobson
Resonance's proprietary bioelectromagnetic medical technology and equipment. The CE-Mark is the
European equivalent to Food and Drug Administration (FDA) marketing approval in the U.S. The
companies expect to execute a separate supply and manufacturing agreement during 1999. Alfonso
Serrato, former senior executive of Medtronic (NYSE:MDT - news) and a director of Jacobson
Resonance Enterprises is also chairman of Serrato Enterprises L.L.C.

Dr. Jerry Jacobson, chairman of Jacobson Resonance Enterprises, said: ''This is a significant
agreement in our company's history and should allow us to establish a global presence in the field of
bio-electromagnetic resonance. We look forward to long-term cooperation with Serrato Enterprises
in this initiative.''

Jacobson Resonance Enterprises Inc., a leader in the emerging field of bio-electromagnetic
resonance, is conducting double-blind randomized clinical studies at four sites in seeking FDA
approval for the treatment and relief of chronic pain of osteoarthritic knees in the U.S.

Forward-looking statements in this release are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to
certain risks and uncertainties detailed in the company's filings with the Securities and Exchange
Commission.

Contact:

Jacobson Resonance Enterprises Inc., Boca Raton
Investor Relations: Frank A. Chaviano
561/477-8020 Tel, 561/477-6101 Fax
Web: www.jrse.com

T.A.P. was compensated in the amount of 50,000 shares for the promotion on JRSE, from L.B.I. Group, INC.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext